Hollis-Eden Pharmaceuticals, Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects

March 18, 2008--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced positive preliminary data from its ongoing 28-day Phase I/II clinical trial in obese insulin resistant subjects with its investigational drug candidate TRIOLEX (HE3286). TRIOLEX is a first-in-class adrenal hormone insulin sensitizer focused on the regulation of unproductive inflammation. Preliminary data to date indicate that TRIOLEX is safe and well tolerated at all doses studied. In addition, the preliminary data thus far suggest that TRIOLEX is reducing fasting blood glucose levels and improving insulin sensitivity as evaluated through euglycemic/hyperinsulinemic clamps, an industry standard measurement for assessing whole body glucose metabolism and to test compounds as potential insulin sensitizers for the treatment of type 2 diabetes. The data were presented at IBC's 6TH Annual Conference, Targeting Metabolic Disorders, being held March 17 through 19 in Chapel Hill, North Carolina, by Jaime Flores-Riveros Ph.D., Vice President of Metabolism and Endocrinology at Hollis-Eden... Hollis-Eden Pharmaceuticals' Press Release -